Morgan Stanley Marker Therapeutics, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.24 - $4.58 $1 - $22	5 Added 0.03%	19,089 $5,000
Q3 2022 Nov 14, 2022	SELL	$0.3 - $3.73 $0 - $11	-3 Reduced 0.02%	19,084 $7,000
Q2 2022 Oct 27, 2022	SELL	$0.26 - $0.46 $975 - $1,726	-3,753 Reduced 16.43%	19,087 $6,000
Q2 2022 Aug 15, 2022	SELL	$0.26 - $0.46 $975 - $1,726	-3,753 Reduced 16.43%	19,087 $6,000
Q1 2022 Oct 27, 2022	BUY	$0.37 - $1.0 $1,388 - $3,753	3,753 Added 19.66%	22,840 $10,000
Q1 2022 May 13, 2022	SELL	$0.37 - $1.0 $4,055 - $10,960	-10,960 Reduced 32.43%	22,840 $10,000
Q4 2021 Feb 14, 2022	SELL	$0.95 - $1.72 $2,415 - $4,373	-2,543 Reduced 7.0%	33,800 $32,000
Q3 2021 Nov 15, 2021	BUY	$1.68 - $2.88 $61,056 - $104,667	36,343 New	36,343 $61,000

475K

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $292M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.